The interstitial lung disease market is projected to grow at a CAGR of 8.7% from 2026-2036, driven by emerging therapies and pipeline candidates. The market was valued at USD 6 billion in 2025 across seven major markets, with the US accounting for 83% of the market. Key developments include FDA approval of nerandomilast (JASCAYD) for progressive pulmonary fibrosis and multiple late-stage candidates addressing immune dysregulation and fibrotic signaling.

RTW Investments established a new $193 million position in Apellis Pharmaceuticals by acquiring 7.67 million shares in Q4 2025. Despite a 29% stock decline over the past year, the investment signals confidence in the company's commercial-stage biotech portfolio, which generated $689 million in product revenue driven by its flagship therapy. The position represents a calculated pivot toward more durable revenue streams within a portfolio focused on high-growth biotech names.

Alumis shares surged 94.53% following positive Phase 3 trial results for envudeucitinib, an oral TYK2 inhibitor for psoriasis that met primary and secondary endpoints. The company announced plans to raise $175 million in capital to support commercialization of the drug and its pipeline. The broader market rose modestly with the S&P 500 gaining 0.62% and Nasdaq up 0.65%.

Ten large-cap stocks experienced significant declines last week. Nike fell 12.81% due to a 17% decline in Greater China sales and analyst downgrades. ARM Holdings dropped 9.77% following Goldman Sachs and Bank of America downgrades. Other major losers included Lennar (9.94% decline after earnings miss), Marathon Petroleum (9.42%), Phillips 66 (8.84%), Coupang (8.52%), BitMine Immersion (9.15%), Insmed (11.37%), Entegris (5.90%), and ServiceNow (0.78%).

Nasdaq announced its annual Nasdaq-100 Index reconstitution, adding six companies and removing six others, effective December 22, 2025. The changes reflect the dynamic composition of leading non-financial companies across various sectors.

Billionaire investor Stanley Druckenmiller has invested 30% of his portfolio in three biotech stocks: Natera, Insmed, and Teva Pharmaceutical Industries, demonstrating strong confidence in the biotech sector's potential.

The DPP1 inhibitor market is experiencing significant growth, driven by BRINSUPRI's approval for non-cystic fibrosis bronchiectasis and increasing prevalence of respiratory diseases. Multiple emerging therapies are advancing in clinical trials, with potential to transform treatment landscapes.

Insmed's BRINSUPRI receives FDA approval as the first therapy for non-cystic fibrosis bronchiectasis, marking a significant breakthrough in treating a condition with high unmet medical needs. The drug targets DPP1 and is expected to generate peak sales of around $5 billion.

The Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market is expected to grow significantly between 2025-2034, driven by improved diagnostic techniques, disease recognition, and emerging therapies targeting functional improvement and disease progression.

The article discusses three stocks that could see a price increase due to the upcoming Russell index rebalancing: Sprouts Farmers Market (SFM), Insmed (INSM), and FTAI Aviation (FTAI).

Insmed's treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension met its primary and secondary endpoints, exceeding analysts' expectations. Analysts have raised their price targets for Insmed, citing the strong data and upcoming catalysts.

The report forecasts the bronchiectasis treatment market to reach $3.7 billion by 2033, driven by emerging pipeline agents expected to contribute an additional $1.8 billion in sales.